Focused On-demand Library for R-spondin-4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q2I0M5

UPID:

RSPO4_HUMAN

Alternative names:

Roof plate-specific spondin-4

Alternative UPACC:

Q2I0M5; A2A2I6; Q9UGB2

Background:

R-spondin-4, also known as Roof plate-specific spondin-4, plays a pivotal role in the activation of the canonical Wnt signaling pathway. It functions as a ligand for LGR4-6 receptors, facilitating the association with phosphorylated LRP6 and frizzled receptors activated by extracellular Wnt receptors. This activation enhances the expression of target genes pivotal for cellular processes.

Therapeutic significance:

R-spondin-4's involvement in the non-syndromic congenital nail disorder 4, characterized by anonychia or hyponychia, underscores its potential as a therapeutic target. Understanding the role of R-spondin-4 could open doors to potential therapeutic strategies for treating nail disorders and possibly other Wnt pathway-related conditions.